US2011301327A1PendingUtilityA1

Epitope analogs

Assignee: LIU LIPINGPriority: Jun 17, 2004Filed: Feb 28, 2011Published: Dec 8, 2011
Est. expiryJun 17, 2024(expired)· nominal 20-yr term from priority
A61P 35/02A61P 35/00A61P 37/04C07K 14/4748A61K 38/00C07K 7/06A61P 31/12C07K 14/47C07K 14/435
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.

Claims

exact text as granted — not AI-modified
1 - 43 . (canceled) 
     
     
         44 . A method of making a T cell epitope analogue comprising,
 providing an amino acid sequence of a segment of a target-associated antigen, the segment having known or predicted affinity for the peptide binding cleft of a MHC protein,   changing at least one amino acid of the sequence corresponding to an anchor position of a MHC binding motif to Nle or Nva, and   synthesizing a peptide comprising the changed sequence.   
     
     
         45 . A T cell epitope peptide analogue wherein the analogue differs from a native epitope peptide by replacement of at least one native residue corresponding to an anchor position of a MHC binding motif with a Nle or Nva residue.

Join the waitlist — get patent alerts

Track US2011301327A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.